"Financial Relationships Likely to Be a Focus in Life Sciences Enforcement and Litigation"

by Skadden, Arps, Slate, Meagher & Flom LLP
Contact

For more than a decade, the Department of Justice (DOJ) has zealously pursued enforcement actions against the health care industry. Life Sciences EnforcementGiven the continued growth in government spending on health care and the billions of dollars in revenue that are paid to the federal government as a result of these cases, we expect this focus to continue. Nevertheless, in recent years we have seen a notable shift in the types of cases that the government is pursuing, away from so-called off-label promotion practices and toward the financial and commercial relationships between health care providers and companies.

In 2016, we expect DOJ to continue focusing on financial relationships with physicians and that recent DOJ guidance may spur an increased effort to hold individuals criminally and civilly responsible in these investigations. Additionally, the unrelenting flow of qui tam lawsuits means federal enforcement agencies will continue to investigate allegations that providers and others submitted false claims for payments to federal health care programs.

Historically, federal criminal and civil investigations have focused on the following types of alleged conduct:

  • claims submitted for a service, drug or device that was not medically necessary;
  • a health care professional prescribing a service, drug or device based on inducements the manufacturer provided;
  • a hospital, managed care organization or pharmaceutical benefit manager including a product on its formulary because of a manufacturer's inducement;
  • claims submitted for a drug or device that was promoted for off-label use and where the physician would not have prescribed the product but for that off-label promotion; and
  • claims paid for a drug or device based on false or misleading information provided in connection with reimbursement support services.

Financial Relationships With Physicians and Other Health Care Professionals

As in past years, DOJ continues to actively investigate life science companies' financial relationships with physicians and other health care professionals, with particular focus on speaker programs. At least two of the significant pharmaceutical or medical device settlements in 2015 involved allegations of improper inducements through these programs. Of note, the allegations in these cases stretched beyond the question of whether the programs were conducted in exchange for payment and also focused on whether their nature, quality and content were of adequate value for the payment made. Given the likely continued government scrutiny of these relationships, many companies are choosing to enhance their assessments of their speaker programs.

Cooperation and Focus on Individuals

In September 2015, Deputy Attorney General Sally Quillian Yates issued a memorandum (Yates Memorandum) outlining six "steps" prosecutors are required to take when investigating a company, in order to ascertain whether there are responsible individuals who also should be charged. While the prosecution of individuals is not new, the Yates Memorandum suggests that DOJ is now going further, for example by directing prosecutors to withhold all cooperation credit unless corporations provide all relevant facts about individual(s) involved in alleged corporate misconduct. Recent indictments also demonstrate that DOJ's approach to prosecuting individuals is evolving, for instance by charging individuals with securities fraud in addition to violations of the Food, Drug and Cosmetic Act. It remains to be seen how the Yates Memorandum will affect prosecutors’ charging decisions, but it may portend an uptick in prosecutions of individuals, something DOJ and the Food and Drug Administration (FDA) have long threatened. (See “Aggressive Government Enforcement Continues: How Will Individual Prosecutions Impact Activity Against Institutions?”)

The Slow Demise of Truthful, Nonmisleading Off-Label Promotion

Despite public statements to the contrary, the court decisions in United States v. Caronia and Amarin Pharma, Inc. v. United States Food & Drug Administration appear to have had some impact on DOJ's pursuit of off-label enforcement in cases where there is no evidence of false or misleading statements by a manufacturer. In Caronia, the U.S. Court of Appeals for the Second Circuit ruled in 2012 that restricting off-label marketing that was not misleading or untruthful would violate the First Amendment. Following that decision, Amarin sought an injunction specifically allowing off-label promotion, and in August 2015 the district court granted it, ruling that Amarin's statements were truthful and not misleading and thus protected by the First Amendment. (See September 28, 2015, Skadden client alert “The Future of Government Regulation, Enforcement of Off-Label Promotion.”) Unless and until other circuits reject the Caronia holding, Amarin may substantially limit FDA's ability to prohibit truthful and nonmisleading speech outside a product's approved labeling. In addition, there likely will be a steady flow of litigation similar to Amarin until FDA issues guidance to the industry that demonstrates its commitment not to engage in regulatory or enforcement actions that necessarily or consequently abridge manufacturers’ First Amendment rights. To avoid direct First Amendment challenges, DOJ likely will direct its efforts toward cases with evidence of false and misleading statements. We also expect DOJ and FDA will closely examine a company's conduct rather than its marketing designed to promote a product for an unapproved use.

For additional information on health care enforcement and litigation trends in the United States and beyond, read “Getting The Deal Through: Healthcare Enforcement & Litigation.”

This article is part of Skadden's 2016 Insights – Regulatory Developments.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Skadden, Arps, Slate, Meagher & Flom LLP | Attorney Advertising

Written by:

Skadden, Arps, Slate, Meagher & Flom LLP
Contact
more
less

Skadden, Arps, Slate, Meagher & Flom LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.